<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Erenumab-aooe is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to the calcitonin gene-related peptide receptor. Erenumab-aooe is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa.</p><p>AIMOVIG (erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous administration. Each 1 mL 70 mg single-dose prefilled autoinjector and 70 mg single-dose prefilled glass syringe contains 70 mg erenumab-aooe, acetate (1.5 mg), polysorbate 80 (0.10 mg), and sucrose (73 mg). Each 1 mL 140 mg single-dose prefilled autoinjector and 140 mg single-dose prefilled glass syringe contains 140 mg erenumab-aooe, acetate (2.0 mg), polysorbate 80 (0.10 mg), and sucrose (65 mg). Enclosed within the autoinjector is a single-dose, prefilled glass syringe. The solution of AIMOVIG has a pH of 5.2.</p></section>

AIMOVIG

1 ML erenumab-aooe 140 MG/ML Auto-Injector

1 ML erenumab-aooe 140 MG/ML Auto-Injector [Aimovig]

1 ML erenumab-aooe 140 MG/ML Prefilled Syringe

1 ML erenumab-aooe 140 MG/ML Prefilled Syringe [Aimovig]

1 ML erenumab-aooe 70 MG/ML Auto-Injector

1 ML erenumab-aooe 70 MG/ML Auto-Injector [Aimovig]

1 ML erenumab-aooe 70 MG/ML Prefilled Syringe

1 ML erenumab-aooe 70 MG/ML Prefilled Syringe [Aimovig]

Aimovig

erenumab

<section class="Section" data-sectioncode="34089-3"><a name="LINK_2c8e4016-3376-4164-bb3b-b7547946b92d"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Fremanezumab-vfrm is a fully humanized IgG2Δa/kappa monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Fremanezumab-vfrm is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The antibody consists of 1324 amino acids and has a molecular weight of approximately 148 kDa.</p><p>AJOVY (fremanezumab-vfrm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous injection, supplied in a single-dose 225 mg/1.5 mL prefilled autoinjector and a single-dose 225 mg/1.5 mL prefilled syringe. </p><p>Each prefilled autoinjector or prefilled syringe delivers 1.5 mL of solution containing 225 mg fremanezumab-vfrm, disodium ethylenediaminetetraacetic acid dihydrate (EDTA) (0.204 mg), L-histidine (0.815 mg), L-histidine hydrochloride monohydrate (3.93 mg), polysorbate-80 (0.3 mg), sucrose (99 mg), and Water for Injection, and has a pH of 5.5.</p></section>

AJOVY

1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector

1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector [Ajovy]

1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe

1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy]

Ajovy

fremanezumab

Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site reactions and constipation. However, there are no reported instances of drug interactions with Aimovig.

Aimovig is FDA approved for the following indications: Migraine prevention. 


Report Adverse Event 

Prescribing Information

Prescribing Information - Spanish

Medication Guide: Latex containing Pen 

Medication Guide: Non-Latex Pen 

Submit MSL Request 

Pharmacy List 

Online Sample Form [Connect With A Rep Pop-Up]

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

PA Checklist 

Enroll in Patient Savings Program 

Amgen Safety Net Foundation Eligibility Check 

Mechanism of Action (MOA)

Efficacy (vs Topiramate)

Efficacy (Pivotal & Long-Term)

Efficacy (Chronic Migraine)

Safety Profile (vs Topiramate)

Safety Profile (Pivotal & Long-Term)

Dosing 

Other HCP Resources 

About Aimovig 

Taking Aimovig

Side Effects

Patient Stories 

AimAlly Support Program 

Patient Resources 

Aimovig Start Guide 

Doctor Discussion Guide 

Instructions For Use (Video): Migraine Prevention 

Instructions For Use [Prefilled SureClick Autoinjector 70mg/ml]: Migraine Prevention 

Instructions For Use [Prefilled SureClick Autoinjector 140 mg/mL]: Migraine Prevention 

Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side effect is injection site reactions. Ajovy does not seem to cause constipation. Additionally, there are no known drug interactions.

Ajovy is FDA approved for the following indications: Migraine prevention. 


Aimovig®(erenumab)	Ajovy®(fremanezumab)

Prescription Only Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...	Prescription Only Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...
Dosage & Administration
Administration
Subcutaneous . Learn more.	Subcutaneous. Learn more.
Dosing
70 mg once monthly or 140 mg once monthly (for some patients). Learn more.	225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.
Latin Shorthand
70 mg/mo or 140 mg/mo. Learn more.	225 mg/mo or 675 mg q3mo. Learn more.
Adverse Reactions
The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.	The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
$5. Learn more.	$5. Learn more.
Annual Cap
Patient specific maximum benefit.. Learn more.	Patient specific maximum benefit.. Learn more.
Assistance Expiration
Calendar year. Learn more.	12/31/2023. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available

Aimovig® Alternatives